Condition: Hepatocellular Carcinoma · Sponsor: AstraZeneca
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | La Jolla, California, United States | Not Yet Recruiting |
| Research Site | Los Angeles, California, United States | Not Yet Recruiting |
| Research Site | Baltimore, Maryland, United States | Not Yet Recruiting |
| Research Site | St Louis, Missouri, United States | Recruiting |
| Research Site | Hackensack, New Jersey, United States | Not Yet Recruiting |
| Research Site | Houston, Texas, United States | Recruiting |
| Research Site | Chengdu, China | Not Yet Recruiting |
| Research Site | Guangzhou, China | Recruiting |
| Research Site | Harbin, China | Not Yet Recruiting |
| Research Site | Shanghai, China | Recruiting |
| Research Site | Pokfulam, Hong Kong | Not Yet Recruiting |
| Research Site | Shatin, Hong Kong | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06795022